-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PvmJCjD8/v//KtY1awFbjZzIK3oqEOWV15s3qfYl2alU+mOyADxz0A/ZZGPaN3uU Yr4IhuREAcEeLe5717Pv1A== 0001036050-97-000721.txt : 19970912 0001036050-97-000721.hdr.sgml : 19970912 ACCESSION NUMBER: 0001036050-97-000721 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19970818 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19970829 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-06533 FILM NUMBER: 97673401 BUSINESS ADDRESS: STREET 1: 31 NEWBURY ST STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6178908263 MAIL ADDRESS: STREET 1: 31 NEWBURY STREET STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 8-K 1 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) August 18, 1997 --------------- BOSTON LIFE SCIENCES, INC. ---------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 0-6533 87-0277826 - ------------------------------- ------ ------------------------------- (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File No.) Identification No.) 31 Newbury Street, Suite 300 Boston, Massachusetts 02116 - ---------------------------------------- --------- (Address of principal executive offices) Zip Code Registrant's telephone number, including area code (617) 425-0200 --------------- Item 5. Other Events. ------------- Boston Life Sciences, Inc. announced that it had completed its Phase III trial for Therafectin(R), its oral drug for the treatment of Rheumatoid Arthritis. The double-blind, placebo controlled trial enrolled 218 patients at 25 sites in the U.S. Results are expected to be available within the next six to eight weeks, after clinical data has been collected from the sites and analyzed. This trial compared Therafectin to placebo in patients with active Rheumatoid Arthritis over a 20 week period. The study was designed with very clear measurable end points, and therefore unambiguous results are expected. BLSI is engaged in the research and development of novel treatments for cancer, autoimmune diseases, and central nervous system disorders. Item 7. Exhibits. -------- The following Exhibits are filed as part of this report on Form 8-K: 99.1 Press Release, dated August 18, 1997. SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto authorized. BOSTON LIFE SCIENCES, INC. Dated: August 28, 1997 By: /s/ Joseph Hernon ---------------------- Joseph Hernon Chief Financial Officer BOSTON LIFE SCIENCES, INC. CURRENT REPORT ON FORM 8-K EXHIBIT INDEX Exhibit No. Page - ----------- ---- 99.1 Press Release, dated August 18, 1997 5 EX-99.1 2 PRESS RELEASE Exhibit 99.1 FOR IMMEDIATE RELEASE BOSTON LIFE SCIENCES ANNOUNCES THE COMPLETION OF ITS PHASE III THERAFECTIN TRIAL Boston, MA -- August 18, 1997--Boston Life Sciences, Inc. (NASDAQ: BLSI) announced that it has completed its Phase III trial for Therafectin(R), the Company's oral drug for the treatment of Rheumatoid Arthritis. The double-blind, placebo-controlled trial enrolled 218 patients at 25 sites in the U.S. Results are currently expected to be available within the next six to eight weeks, after clinical data has been collected from the sites and analyzed. "We are pleased to have completed this pivotal trial, which compared Therafectin to placebo in patients with active Rheumatoid Arthritis over a 20 week period," said Dr. Marc Lanser, Chief Scientific Officer of BLSI. "The study was designed with very clear measurable end points, and we therefore expect unambiguous results", added Dr. Lanser. BLSI is developing novel treatments for cancer, autoimmune diseases, and central nervous system disorders. In addition to THERAFECTIN, BLSI's products in clinical trials or in preclinical development include Troponin I, a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. For additional information contact: Marc E. Lanser, M.D. or S. David Hillson Chief Scientific Officer President and CEO 617-425-0200 617-425-0200 ### -----END PRIVACY-ENHANCED MESSAGE-----